New third-party app connections, more compatible devices and in-clinic Bluetooth uploads to better connect patients and their data with clinicians

MOUNTAIN VIEW, California/US and GOTHENBURG, Sweden, 17 September 2019 — Glooko®, the leader in diabetes data management solutions, continues to strengthen its global position with the introduction of several new features and expanded connectivity capabilities for the diasend® by Glooko system at this week’s 55th annual meeting of the European Association for the Study of Diabetes (EASD). The additional device integration partnerships, new ways to upload patient data in clinic, and feature enhancements will be unveiled at the September 17-20 meeting in Barcelona.

Increased device compatibility
At EASD, Europe’s largest and most prominent diabetes meeting, Glooko will share new device integrations it has developed with two new partners:

Additional ways to upload data in-clinic
At the beginning of 2019, NFC connectivity (near-field communication) was introduced in the hardware of the diasend® by Glooko system, which serves as a “one-stop shop” for patients when visiting their health care provider, because it’s able to upload data from numerous devices regardless of brand. Now, BLE (Bluetooth Low Energy) is also added to the mix of ways to upload data to the diasend® solution, providing greater flexibility for the upload process and making clinic/patient interaction even easier. Both NFC and BLE are expected to become increasingly common in diabetes devices during the next couple of years.
“Glooko is pleased to bring additional value to our customers with new data solutions and device integrations on our trusted diasend data management platform,” said Russ Johannesson, CEO of Glooko. “It exemplifies the increasing momentum of Glooko solutions, which provide comprehensive patientbased diabetes data to physicians, better connecting them with their patients. Our greater reach with diasend by Glooko enables healthcare professionals to better focus on value-based outcomes for the patients they serve.”

Prominent speakers at EASD
On the scientific front, Glooko will offer in-booth presentations from two renowned speakers:

“We are proud of the array of diasend by Glooko news that will be showcased at EASD this year, and how it highlights our continuous innovation. We are adding more options to our comprehensive list of compatible devices and introducing new ways for them to function seamlessly with our universal solution,” said Anders Sonesson, Global VP and General Manager of Glooko. “As always, we put our users at the heart of everything we do, and these additions will facilitate the patient/clinic interaction from both sides.”

*Available in selected European countries.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts:
Sebastian Persson
Marketing Director EMEA/APAC
[email protected]
+46 701 46 10 10

Jeff Christensen
SignalWest Public Relations
+1 831-566-0275
[email protected]

Accomplished finance and operations leader brings deep experience in SaaS and healthcare technology to continue acceleration of diabetes data management leader’s growth

MOUNTAIN VIEW, Calif., July 16, 2019—Glooko®, the global leader in diabetes data management solutions, today announced the appointment of Stephen Lien as Chief Financial Officer. Lien comes to Glooko with relevant and extensive experience serving in senior leadership roles in finance and operations across a range of related industries. Some of these include healthcare technology, consumer software, enterprise software, digital media, and software as a service (SaaS). Glooko serves healthcare providers, payers and people with diabetes through its leading FDA-cleared, HIPAA-compliant diabetes management platform.

“We’re very excited to have a seasoned finance and operations executive of Steve’s caliber joining the Glooko team, especially at this stage in our company’s development,” said Russ Johannesson, CEO of Glooko. “Steve is a leader with a strong track record for not only accelerating revenue and maximizing returns but also for scaling global businesses and taking them to the next level, and most recently, that has been with organizations focused on SaaS solutions in the healthcare space.”

Lien comes to Glooko having served most recently as CFO of PipelineRx, a healthcare SaaS technology company that provides pharmacy solutions to inpatient and outpatient pharmacies. Responsible for leading the finance, pharmacy operations, HR and compliance functions at PipelineRx, Lien managed the company’s transformation from a tech-enabled services provider to a technology SaaS subscription company. He also led the company in a Series F Growth Equity round of funding that raised $18 million from strategic investors and $15 million through debt financing, and he was instrumental in growing the company’s recurring annual contract value (ACV) more than 250 percent, year over year.

Prior to PipelineRx, Lien successfully served as CFO at several other companies, including Smart Tuition and SmartCare, a holding company for two SaaS providers (one in the K-12 education space and the other in child care services), where he provided strategic and financial advice leading to the sale of Smart Tuition to Blackbaud for $190 million. Prior to that, as CFO of Skrill Limited—Moneybookers, Inc., a leader in e-commerce and digital payments, Lien built the financial foundation in the U.S. that enabled the sale of the company to CVC Partners for €600 million.

Lien is particularly enthusiastic to be coming to Glooko, where he can continue his work in healthcare technology.

“The global Glooko platform and database have grown into one of the largest in diabetes, serving more than 2.2 million people with diabetes, connecting them with their health care providers and generating powerful insights that are helping guide treatment decisions,” Lien said. “I’m excited to be joining Russ and the rest of the Glooko team in accelerating that growth and scaling the company as we strive to serve more payers, providers, and people with diabetes.”

Lien holds a bachelor’s degree in economics and business administration from the University of California, Berkeley’s Haas School of Business.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 23 countries across 15 languages. Learn more by visiting www.glooko.com.

Media contact:

Holly McGarraugh

Glooko

510-282-2852

 

Jeff Christensen

SignalWest Public Relations

831-566-0275

[email protected]

 

SAN DIEGO and MOUNTAIN VIEW, Calif., June 5th, 2019 – Companion Medical, a leader in the development of advanced insulin delivery technology to improve diabetes care, and Glooko, a leader in diabetes data visualization and management, have announced an integrated data partnership agreement that will enable insulin data from users of the InPen™ Smart Insulin Injection Pen to be integrated into the Glooko® Enterprise diabetes data management system and Glooko® Mobile App. This integration, through Apple Health, will allow users to automatically integrate their insulin data with the Glooko diabetes data management system for clinical evaluation by their healthcare professionals.

“We are thrilled to be working with Glooko to bring integrated multiple daily injection (MDI) insulin data into the Glooko system,” said Companion Medical’s Chief Executive Officer Sean Saint. “Our mission is to bring insulin data together with glucose and other contextual data in a way that is seamless, easy and automatic for both healthcare professionals and their patients. Our partnership with Glooko is an important step in that mission.”

The announcement of this integration is significant because InPen is the first “smart” insulin pen to introduce its data integration and compatibility with the Glooko platform in the U.S. More than 70 percent of the 7.4 million insulin users in the U.S. take their insulin via MDI, and of those, approximately half take it using an insulin pen.

“We are excited to launch support for InPen on the Glooko platform,” said Russ Johannesson, CEO of Glooko. “InPen is an innovative solution for calculating insulin doses and tracking insulin injection data. We feel users will get tremendous value out of seeing this data correlated with the food, activity, and glucose information in Glooko to help them make informed treatment decisions when they dose and see diabetes insights and trends over time that may not have been previously known.”

The partnership allows people living with diabetes who use InPen to integrate their multiple daily injection regimen data, both long-acting and rapid-acting, into the Glooko diabetes data platform.

“We believe this is a huge step forward in the development of integrated diabetes management because it allows data never seen before, both long and short-acting insulin, to be integrated with other diabetes data residing in the Glooko platform without the need for downloading or manually entering data,” said Companion Medical’s Chief Technology Officer Mike Mensinger.

InPen is available in the U.S. by prescription only. The Glooko Mobile App is available for free download in the Apple Store and Android Play.

For more information, visit www.companionmedical.com and www.glooko.com.

About Companion Medical

Companion Medical is a leader in the development of advanced technology to improve diabetes care. InPen™, the first and only FDA-cleared smart insulin pen, combines an innovative diabetes management app with a Bluetooth® enabled pen injector to simplify the constant tracking, monitoring and calculating required for insulin therapy.  InPen addresses many of the issues that people living with diabetes face on a daily basis, including missed insulin doses, miscalculated insulin doses and insulin stacking.

About Glooko

Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000 clinic locations in 23 countries across 15 languages. Learn more by visiting www.glooko.com.

Media contact:

Companion Medical

Amanda Sanders, MBA

Senior Manager of Marketing

858-522-0252 ext. 6342

www.companionmedical.com

[email protected]

Glooko

Jeff Christensen

SignalWest Public Relations

831-566-0275

[email protected]

Leading endocrinologist recognized as an expert in diabetes data analytics brings broad patient care and clinical research experience to diabetes data management leader

MOUNTAIN VIEW, Calif., May ​21,​ 2019 — ​Glooko, the leader in diabetes data management solutions, today announced the appointment of Mark Clements, MD, PhD, CPI, FAAP, as Chief Medical Officer. Dr. Clements joins the senior management team of Glooko having served on its medical advisory board since it was formed in 2015 to provide expertise to the organization in the areas of clinical studies and diabetes analytics.

Dr. Clements comes to Glooko from the University of Missouri-Kansas City School of Medicine, where he is Associate Professor of Pediatrics. He is also a pediatric endocrinologist at Children’s Mercy Kansas City, where he serves as Director of Pediatric Endocrine/Diabetes Clinical Research and Medical Director for the Pediatric Clinical Research Unit. He will continue his work with the medical school and Children’s Mercy as he also takes on his new role with Glooko.

“We’re thrilled to have Mark join our executive leadership team at Glooko and bring the depth of experience he has in patient care as well as medical research and education,” said Russ Johannesson, CEO of Glooko. “This background combined with his expertise in turning data and analytics into practical insights for treating people with diabetes will be a significant advantage for us, especially as he provides leadership in the development of our future product portfolio and adds his perspective as clinician and investigator to our research efforts.”

Regularly seeking to incorporate effective innovations that will enhance the care of his pediatric diabetes patients, Dr. Clements is also a clinical researcher of new diabetes treatments and technologies, having served as a principal investigator or co-investigator in more than 30 clinical studies and patient registries.

One of his key interests is in applying analytics to the data people with diabetes collect on their various diabetes or biometric devices. He’s particularly interested in how persons with diabetes can safely and securely share their own health-related data with their healthcare providers. He is also interested in how new analytic methods and new data types can help people and their healthcare providers work together to make adjustments in their daily self-management that will lead to better glucose control

“With diabetes technology today, the person with diabetes is able to accumulate enormous amounts of data about his or her diabetes and share it safely with healthcare professionals, and that ability is expanding rapidly,” said Dr. Clements. “That can provide a huge advantage in helping patients be more effective in managing their diabetes, but only if we provide tools that can help them see their data in the form of practical insights that they and their clinicians can use to effectively guide diabetes management. As the clear leader and a trusted partner in

diabetes data management, Glooko is in a unique position to forge the path toward keeping data private and secure while making it usable and practical for patients and their providers, and I’m excited to be joining the organization in leading that effort.”

Consistent with his research and leadership experience as well as his desire to find effective treatments for children with diabetes, Dr. Clements has also served as Pediatric Chair of the T1D Exchange Clinic Registry of the T1D Exchange, a nonprofit research and collaboration organization dedicated to accelerating novel therapies to improve the care of people living with Type 1 diabetes.

Dr. Clements has published extensively in peer-reviewed medical journals and is sought after as a speaker, particularly on the topic of diabetes analytics and insights.

He earned his medical degree and a PhD in developmental neuroscience from Washington University Medical School in St. Louis, and he completed a residency in pediatrics and a fellowship in pediatric endocrinology at the University of Missouri-Kansas City School of Medicine and Children’s Mercy Hospital.

Dr. Clements is board certified in pediatric endocrinology by the American Board of Pediatrics and is a fellow of the American Academy of Pediatrics (FAAP). He is also recognized as a certified principal investigator (CPI) by the Association of Clinical Research Professionals.

About Glooko

Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and fitness and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000 clinic locations in 23 countries across 15 languages. Learn more by visiting www.glooko.com​.

Media Contact:

Holly McGarraugh 510-282-2852

Free app enables effective self-management plus the ability for providers to remotely monitor their diabetes populations

March 5, 2019, Mountain View, CA.  Glooko, the leader in diabetes data management, announced today its mobile app (available for Android and iOS) is now free* for any person with diabetes.  Previously, there was a subscription fee for individuals not sponsored through their provider, health plan, or employer.  The mobile app can help users effectively self-manage their condition through glucose tracking, insights delivery and by correlating food, exercise and medication data to create actionable insights. For healthcare providers who use Glooko for remote monitoring, their entire patient population now will be available for them to provide this service. Glooko remote monitoring programs have been demonstrated to help participants improve outcomes, including improving average blood glucose by 12% and reducing the occurrence of hyperglycemia by 15%**; this change allows a broader population to experience these clinical benefits.

Remote monitoring also offers providers the ability to have efficient in-clinic appointments, as patients can sync their device data at home rather than doing so in the office, as well as access new revenue streams via newly available CPT codes for remote patient monitoring.  These codes provide reimbursement for key tasks required to remotely monitor patients, including training patients, collecting and monitoring remotely synced data, and communicating with patients about changes to their treatment plan based on the data they sync remotely.

“Glooko strives to improve the lives of people with diabetes by providing actionable insights to inform care decisions,” said Russ Johannesson, CEO of Glooko.  “I am thrilled we are removing the subscription fee for users of the mobile app – this will allow anyone who wants to use Glooko for self-management to be able to do so.  I am also excited about the ability for providers to remotely monitor larger patient populations. Diabetes is a very complicated, data-intensive condition; more frequent support for patients is critical in helping them better manage their diabetes.”

All features of the Glooko mobile app will be available in the free version, including the ability to sync data from compatible blood glucose meters, insulin pumps, continuous glucose monitors, and fitness trackers, the ability to log food (including via the recently released barcode scanner), medication, and activity, access to interactive charts and graphs, and the ability to easily send reports to providers and care teams. Glooko also announced today the support for the first implantable long term glucose sensor, the Senseonics Eversense® Continuous Glucose Monitoring System (CGM), available in the free app.  Users of the Eversense CGM simply need to connect their Eversense account to Glooko, and their Eversense data will be available along with blood glucose, insulin, food, and any other information logged.


*one-time hardware costs may apply
**improvement after three months for users in Glooko remote monitoring programs with coaching

Media contact:
Jennivine Lee Simon
[email protected]

About Glooko

Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the diasend® and Glooko diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems sync data from 190+ of the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient data such as glucose level, food, insulin, medications, blood pressure and weight data. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000 clinic locations in 23 countries across 15 languages. Learn more by visiting www.glooko.com.

Gothenburg, Sweden / Mountain View, CA, 19 February 2019 – Glooko, the leader in diabetes data management, is gearing up for the ATTD trade show (Advanced Technologies & Treatment for Diabetes) with several exciting announcements: the launch of Novo Nordisk connected insulin pens on the diasend® platform, compatibility with the Dexcom G6 continuous glucose monitor – and the release of its Annual Diabetes Report, which will be presented to the audience in Berlin later this week.

In early 2017, Glooko and Novo Nordisk teamed up for the initial pilot of the next generation insulin pens. Enrolled patients used Novo Nordisk’s new connected devices as part of their treatment, and shared captured insulin data with their doctors via the diasend® by Glooko in-clinic solution. With diasend®, doctors were able to see and advise patients based on recorded insulin dose data from connected Novo Nordisk pens without having to invest additional time. Now, to raise the bar for patient convenience even further, Glooko is launching the ability to also upload pen data remotely – straight from any near field communication (NFC) equipped Android phone running the diasend® Mobile App.

“Our partnership with Glooko is already helping healthcare professionals to better understand their patients’ diabetes management,” says Søren Smed Østergaard, Vice President of Digital Health at Novo Nordisk. “By integrating our connected, durable insulin pens with the diasend® Mobile App, we will soon help people manage their disease and access healthcare when they need it.”

“This is a big step in using data to improve diabetes management. Until now, data from insulin pens was self-reported and subject to error, or often simply not captured. Our partnership with Novo Nordisk enables this insulin data to be seamlessly synced to diasend®, where patients and providers can easily see the data correlated with glucose levels, activity information and more. This allows much more informed conversations and decisions about the insulin regimen as well as other aspects of the treatment plan” says Russ Johannesson, CEO of Glooko.

The launch of Novo Nordisk’s first connected insulin pens, NovoPen® 6 and NovoPen Echo® Plus, will commence in early 2019. Any health care provider using diasend® in the clinic, and any patient using the diasend® Mobile App on an NFC equipped Android phone, will be able to sync data from the pens.

In addition, Glooko is also rolling out compatibility with Dexcom’s popular G6 continuous glucose monitoring system for the diasend® solution. This means that PWDs can either upload data to diasend® when visiting their health care provider, via the in-clinic upload solution*, or sync continuously by setting up a cloud-to-cloud connection with their Dexcom CLARITY account. The latter is now also possible through the Glooko product, offered in the US.

Lastly, Glooko is presenting its Annual Diabetes Report at the ATTD trade show in Berlin later this week. With a sum total of almost 15 billion data points, readers will once again get to know which country has the lowest average BG value, countries with the highest frequency of hypoglycemia and which day was the best (most time in range) day for people living with diabetes. Glooko also shares real world examples of how the insights it provides improves outcomes for diabetes populations – on average, populations using the Glooko product experience a 12% improvement in blood glucose within three months. For all of that, and more, check out the full report HERE.

* Country availability may vary.

About Glooko

Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes (PWDs) and their care teams. The Glooko product suite contains the diasend® and Glooko diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems sync data from 190+ of the world’s most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient data such as glucose level, food, insulin, medications, blood pressure and weight data. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million PWDs and are used in 9,000 clinic locations in 23 countries across 15 languages. Learn more by visiting www.glooko.com.

Press contact

Sebastian Persson

Marketing Director EMEA/APAC

[email protected]

+46 701 46 10 10

Glooko now boasts 9,000 clinical locations and 2.2M patients on its platform

January 24, 2019, Mountain View, CA and Gothenburg, Sweden. Glooko, the leader in diabetes data management, had a successful 2018 fueled by strong growth in health system customers, international expansion, and new partnerships. The recent success creates a strong foundation for continued momentum in 2019.  During 2018, Glooko added over two thousand health systems and clinic locations across 23 countries, and achieved near 100% specialty clinic penetration in Sweden and England. Health systems use Glooko’s award winning diabetes data management solution to provide both in-clinic andremote patient support; Glooko now has over 2.2M patients on its platform.  Recent studies have demonstrated that Glooko use can drive better outcomes such as improving average blood glucose and lowering the risk for hyperglycemia1.

Said Dr. Luigi Meneghini, Executive Director of Parkland Health & Hospital System Global Diabetes Program, “We implemented the Glooko platform to streamline downloading data from monitoring devices in the Diabetes & Foot Wound Clinic at Parkland, and importantly, to have that information easily available to providers and other healthcare professionals. We have improved our workflows around the use of patient self-monitored blood glucose (SMBG) data, reduced the need for paper logbooks and enhanced the safeguard of that data. Our providers appreciate the standard interface, data reports and analyses and the ability to share this information with patients during their visit. This is a tool that facilitates the use of SMBG data for the management of hyperglycemia at the point of care and increases the value of that data.”

Glooko continues to add blood glucose meters, insulin pumps, continuous glucose monitors, and other diabetes and health devices to its platform, and in 2018, has entered into partnerships with close to a dozen additional medical device and pharmaceutical companies to support their products.  Glooko now syncs data with over 190 devices globally, including the Omnipod Dash, Dexcom G6, and new innovations such as smart insulin pens, implantable sensors, and patch pumps once they are commercially available. Glooko has also expanded strategic relationships with partners such asNovo Nordisk and Insulet to support new product innovations and expand access to Glooko in new geographies.  With over 12 billion data points, the Glooko database is one of the largest in the diabetes industry and generates powerful insights to help providers and people with diabetes make treatment decisions.

“I’m extremely proud of the success we’ve achieved in 2018, and look forward to accelerating our growth this year,” said Russ Johannesson, CEO of Glooko.  “We continue to invest in our capabilities to provide diabetes insights and decision support to providers and people with diabetes and are excited to introduce enhanced offerings that aim to improve care and lower costs.”

1. Digital Diabetes Management Application Improves Glycemic Outcomes in People With Type 1 and Type 2 Diabetes, Journal of Diabetes Science and Technology, 2017

Bagsværd, Denmark, 1 October 2018 – Novo Nordisk today announced plans to make the durable, connected insulin pens NovoPen® 6 and NovoPen Echo® Plus commercially available across key markets commencing in early 2019. In parallel, to support the future integration of its connected pens with broader digital health solutions, Novo Nordisk has signed new partnership agreements with leading diabetes technology companies that share Novo Nordisk’s vision to improve the lives of people with diabetes: Dexcom, Glooko and Roche.

The partnerships aim to advance the solutions available for people living with diabetes and their healthcare professionals. Building upon its existing work with IBM Watson Health and Glooko, Novo Nordisk aims to seamlessly integrate insulin dosing data from connected pen devices with its partners’ open ecosystems and diabetes management solutions, such as data from continuous glucose monitoring (CGM) systems and blood glucose meters (BGM).

“Our non-exclusive partnership strategy allows us to integrate with the various digital platforms that people are already using to help manage their diabetes,” said Camilla Sylvest, executive vice president of Commercial Strategy & Corporate Affairs at Novo Nordisk. “We firmly believe that this will help more people realise the full benefit of our innovative medicines and begin to ease the mental burden of diabetes treatment for those individuals.”

The launch of Novo Nordisk’s first connected insulin pens, NovoPen® 6 and NovoPen Echo® Plus, will commence in the first quarter of 2019 and roll out to over 50 countries in the coming years. NovoPen® 6 and NovoPen Echo® Plus will eventually be phased in to replace NovoPen® 5 and NovoPen Echo® in countries where those devices are currently available.

“After receiving caregiver feedback, we knew a global roll-out was the right thing to do,” said Camilla Sylvest, referring to a 2017-18 Swedish pilot in collaboration with Glooko. “During the pilot, healthcare providers noted that patient dialogues improved without having to invest additional time.”

Global Head of Roche Diabetes Care Marcel Gmuender added that, “synching Novo Nordisk insulin data with our digital diabetes management solutions like mySugr and Accu-Chek Smart Pix will allow us to enhance quality of care and help create more sustainable healthcare systems.”

Novo Nordisk will also integrate insulin dosing data with Dexcom CGM data in the coming years. “We believe that a fully connected ecosystem represents a significant opportunity to improve the lives of people on multiple daily injections,” said Steve Pacelli, executive vice president of Strategy & Corporate Development at Dexcom.

“We are pleased to extend our collaboration with Novo Nordisk,” said Russ Johannesson, CEO at Glooko. “We are excited about evolving our integrated solutions and look forward to helping more people manage their diabetes via the Glooko platform.”

Beyond launching connected durable devices, Novo Nordisk expects to deliver connectivity for its disposable, pre-filled injection pens later in 2019. In the longer term, Novo Nordisk aims to increase the availability of connected pens and offer solutions for personalised treatment guidance.

 

LONDON–(BUSINESS WIRE)–Jul. 12, 2018– Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that it has partnered with Glooko®, Inc. to connect Insulet’s Omnipod System user data with Glooko+diasend®, the most comprehensive diabetes data management system available, across Europe.

“Insulet and Glooko are dedicated to bringing innovation to diabetes management around the world. We are delighted to work together to provide Omnipod users across Europe the ability to remotely sync data from their Omnipod Systems using Glooko+diasend,” said DJ Cass, General Manager, Insulet Europe. “This combined platform makes their lives easier by allowing people with diabetes to review their blood glucose patterns on their smartphones and monitor the impact of their insulin regimen, diet and physical activity on their diabetes management.”

Insulet’s partnership with Glooko is further proof of its commitment to putting customers first, as it ensures Insulet can continue to be closer to the diabetes community and provide personalised support for Podders™ across Europe.

“Glooko has a long-standing relationship with Insulet and we are very excited to now expand our collaboration even further within the European markets,” said Anders Sonesson, General Manager Glooko Europe. “We are proud to support the Omnipod System with our universal data management solution and our seamless user experience will appeal to numerous health care providers and their patients throughout Europe, taking clinic workflow, remote patient monitoring and overall diabetes treatment plans to new heights.”

Glooko+diasend is currently used at approximately 7,000 provider sites by over 1.5 million users in 23 countries, and the system is offered in 15 languages.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives.

On July 1, 2018, Insulet assumed direct operations of its Omnipod Insulin Management System product line in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as Insulet does in the United States and Canada.

For more information, please visit: www.insulet.com and www.myomnipod.com.

About Glooko:

Glooko provides insights into diabetes by enabling both people with diabetes (PWDs) and their care teams with technology to understand and manage diabetes care. With Glooko, one can easily upload data from more than 160 devices such as blood glucose meters, insulin pumps, CGMs and several fitness and activity trackers — providing timely and verified data and enabling PWDs and care teams to correlate it with diet, exercise, medication and other data. Glooko provides care teams with an easy office data upload solution and a population health app so they can support PWDs during and in-between office visits. Trusted by the world’s leaders in diabetes care, Glooko is used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet’s expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 22, 2018 in the section entitled “Risk Factors,” and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

© 2018 Insulet Corporation. Omnipod, the Omnipod logo and Podders are trademarks or registered trademarks of Insulet Corporation. All rights reserved. Glooko and diasend are trademarks of Glooko, Inc. and used with permission.

Source: Insulet Corporation

Insulet Corporation
Investor Relations and Corporate Communications Contact:
Deborah R. Gordon, +1 978-600-7717
Vice President, Investor Relations and Corporate Communications
[email protected]
or
Media Contact:
Dominic Hulton, +44 20 3941 5374
Vice President, Marketing, Europe
[email protected]

Insights to be shared this weekend at the 
78th Scientific Sessions of American Diabetes Association

Mountain View, Calif. and Gothenburg, Sweden –June 22, 2018, Glooko, the leader in diabetes data management, today announced participation in the 78th Annual American Diabetes Association (ADA) meeting taking place this weekend in Orlando, Fla. At the event, Glooko will demonstrate the new version 5.0 of its diabetes management mobile application and will share results from a recent human factors study on its Mobile Insulin Dosing System (MIDS) for long-acting insulin (LAI) titration, which was FDA cleared earlier this year.

With over 95% of glucose, insulin pump and exercise devices supported, the new Glooko Mobile App focuses on features that add context to glucose and insulin data. Version 5.0 makes tracking personal lifestyle events like exercise, food and medication easier and faster. The new release includes:

“Glooko’s universal platform for diabetes data management not only seamlessly captures data from most diabetes devices in the market, but now makes lifestyle tracking easier than ever before,” said Dave Conn, Chief Commercial Officer at Glooko. He continued, “Adding further insights like food, medication, insulin, exercise and notes about mood, feelings and behaviors provides relevant context to an individual’s glucose readings and helps people with diabetes and clinicians better augment self-care and the overall clinical care plan.”

In addition to demonstrating the new Glooko Mobile App and the recently released version of the Glooko Web App, Glooko will also be presenting a poster at the ADA conference on Saturday, June 23, from 11:30-12:30 pm. The poster covers the results from a recent human factors study on the MIDS application – proving that MIDS is simple, effective, and easy-to-use for people with type 2 diabetes of varying ages, LAI experience, and smartphone use without training or reading a user manual. Participants reported overwhelmingly positive feedback and no participant expressed frustration when completing tasks despite any lack of training or prior experience with digital diabetes tools.

To learn more visit us in booth #1137 on the exhibition floor or come see our poster in the General Poster Session, Category 12-C Clinical Therapeutics/New Technology- Insulins #1055-P.

About Glooko

Glooko provides insights that improve outcomes for people with diabetes (PWDs) and their care teams. Glooko syncs data from the world’s most popular diabetes devices and major fitness and activity trackers and supplies personalized, timely insights based on blood glucose, food, insulin, blood pressure, diet and weight data. Trusted by the world’s leaders in diabetes care, Glooko is used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com